New vaccine targets rare liver cancer's genetic flaw

NCT ID NCT06789198

First seen Feb 16, 2026 · Last updated Jun 02, 2026 · Updated 14 times

Summary

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cells to recognize and attack cancer cells carrying this fusion. The study will enroll about 20 participants who have achieved complete remission after standard treatments, to see if the vaccine is safe and triggers a strong immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Tuebingen

    RECRUITING

    Tübingen, 72076, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Universitätsklinikum Tübingen, Kinderheilkunde I

    NOT_YET_RECRUITING

    Tübingen, 72076, Germany

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.